Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 57 recruiting now later-stage tilt #42 of 28,707 conditions

Coronary Artery Disease: later-stage trial registry

57 of 220 indexed Coronary Artery Disease trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #42 of 28,707 conditions by registered trial count.

220 US clinical trials · 57 currently recruiting · #42 of 28,707 conditions by registered trial count

Coronary Artery Disease: 220 US clinical trials tracked, 57 recruiting.

Coronary Artery Disease is the subject of 220 registered US clinical trials on ClinicalTrials.gov, 57 of them currently open to new participants. 42 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is University of Florida, running 17 of these trials.

Enrollment posture brief

Registry condition coronary-artery-disease

OPEN 57 | RECR 26% | LATE 42 | EARLY 15 | RANK #42 | SPON 17

Nearest open-share peer: Adenocarcinoma (26% recruiting · 27 trials)

Autism Spectrum Disorder49.8%Mild Cognitive Impairment48.5%Sickle Cell Disease44.4%Coronary Artery Disease (thi…26%Diabetes Mellitus23.3%
Open-enrollment share among volume-matched conditions near Coronary Artery Disease

Coronary Artery Disease lists 57 open slots (26% of 220 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Coronary Artery Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Coronary Artery Disease is recruiting below its size-band peers.

    57 of 220 indexed trials (25.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Coronary Artery Disease trials is spread across many organizations.

    University of Florida accounts for 17 of 220 trials (7.7%). 134 distinct sponsors appear on at least one study for this condition label.

  3. Typical Coronary Artery Disease enrolment sits around 266 participants.

    Median target enrolment is 266 among the 220 trials that report a genuine target (sentinel values excluded). 70 of those (31.8%) plan for fewer than 100 participants.

  4. Coronary Artery Disease splits between interventional and observational designs.

    153 interventional and 67 observational studies make up this index (69.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 29Phase 317Phase 425

Open and recent trials

220 total, page 3 of 5

COMPLETED 2,067 participants

An Observational Study of Cholesterol in Coronary Arteries

Infraredx

NCT00831116

COMPLETED Phase 4 2,009 participants

EVOLVE Short DAPT Study

Boston Scientific Corporation

NCT02605447

COMPLETED 2,000 participants

Genotype Information and Functional Testing Study

Scripps Health

NCT00992420

COMPLETED NA 1,629 participants

PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

Sino Medical Sciences Technology

NCT03168776

COMPLETED Phase 3 1,530 participants

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

Boston Scientific Corporation

NCT00823212

COMPLETED 1,501 participants

PLATINUM Diversity

Boston Scientific Corporation

NCT02240810

COMPLETED Phase 2 1,326 participants

TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent

Boston Scientific Corporation

NCT00292474

COMPLETED Phase 3 1,264 participants

TAXUS PERSEUS Workhorse

Boston Scientific Corporation

NCT00484315

COMPLETED Phase 3 1,058 participants

Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions (SIRIUS)

Cordis US

NCT00232765

COMPLETED 1,000 participants

Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy

University of Florida

NCT02724319

COMPLETED 984 participants

Drug Eluting Stent Registry of Thrombosis

Medstar Health Research Institute

NCT00812552

COMPLETED Phase 4 949 participants

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

Gilead Sciences

NCT01425359

COMPLETED NA 808 participants

Enhancing Recovery After Cardiac Surgery

University of California, Los Angeles

NCT00522717

COMPLETED Phase 4 777 participants

ISCHEMIA-Chronic Kidney Disease Trial

NYU Langone Health

NCT01985360

COMPLETED NA 698 participants

Radial Artery Access With Ultrasound Trial

University of California, Irvine

NCT01605292

COMPLETED NA 687 participants

Vitamins in Nitrous Oxide Study

Washington University School of Medicine

NCT00655980

COMPLETED Phase 3 682 participants

Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

AbbVie (prior sponsor, Abbott)

NCT00616772

COMPLETED 600 participants

Predictor of Advanced Subclinical Atherosclerosis

PreMD

NCT00245284

COMPLETED 597 participants

Retrospective Experience Of CIED Implantation

Elutia

NCT04351269

COMPLETED 581 participants

Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)

CardioDx

NCT01117506

COMPLETED 571 participants

Role of Podocan and Wnt Pathway Regulatory Molecules in Coronary Artery Disease

Jennifer Victory, RN, CCRC

NCT02807714

COMPLETED Phase 3 478 participants

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

Bayer

NCT01890434

COMPLETED NA 452 participants

Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations

University of Miami

NCT01651208

COMPLETED NA 450 participants

OPTIMIZE PCI: Multicenter Randomized Trial of OCT Compared to IVUS and Angiography to Guide Coronary Stent Implantation

Abbott Medical Devices

NCT02471586

COMPLETED NA 447 participants

Enhancing Cardiac Rehabilitation Through Behavioral Nudges

Denver Health and Hospital Authority

NCT03834155

COMPLETED NA 431 participants

Disrupt CAD III With the Shockwave Coronary IVL System

Shockwave Medical

NCT03595176

COMPLETED Phase 3 426 participants

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

Bayer

NCT01890421

COMPLETED 418 participants

Observational Study of OCT in a Patients Undergoing FFR

Abbott Medical Devices

NCT01663896

COMPLETED 406 participants

Restore EF Observational Study

Abiomed

NCT04648306

COMPLETED NA 400 participants

Stress Echocardiography and Heart Computed Tomography (CT) Scan in Emergency Department Patients With Chest Pain

Montefiore Medical Center

NCT01384448

COMPLETED NA 400 participants

The Health Access and Recovery Peer Program

Emory University

NCT01725815

COMPLETED 370 participants

GUARD-AKI: Validation of AKI-Sapere in Cardiac Surgery Patients

Sapere Bio

NCT03635606

COMPLETED NA 355 participants

Hemostasis With QuikClot® Radial® Pad Versus TR Band® After Transradial Artery Access

Memorial Healthcare System

NCT03535597

COMPLETED Phase 4 351 participants

Periprocedural Glycemic Control in Patients Undergoing Coronary Angiography

NYU Langone Health

NCT01419652

COMPLETED 350 participants

Fractional Flow Reserve and Intravascular Ultrasound RelationShip STudy

Volcano Corporation

NCT01153555

COMPLETED Phase 2 340 participants

Targeting Inflammation Using Salsalate in CardioVascular Disease

Joslin Diabetes Center

NCT00624923

COMPLETED 330 participants

Frequency Analysis of Coronary Artery Disease

University of Minnesota

NCT01043237

COMPLETED NA 328 participants

The OMEGA Clinical Trial

Boston Scientific Corporation

NCT01419171

COMPLETED NA 296 participants

COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT

CeloNova BioSciences

NCT01925794

COMPLETED NA 287 participants

Evaluating a Low-Literacy Discharge Medication Education Tool

University of California, Los Angeles

NCT00408733

COMPLETED Phase 4 280 participants

Anti-inflammatory Effects of Colchicine in PCI

NYU Langone Health

NCT01709981

COMPLETED Phase 2 270 participants

MARS - Monitored Atherosclerosis Regression Study

Merck Sharp & Dohme

NCT00116870

COMPLETED NA 266 participants

Same Day Discharge (SDD) After Implantable Cardioverter Defibrillator (ICD) Implant

Abbott Medical Devices

NCT01993862

COMPLETED NA 241 participants

Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)

Vasorum

NCT01600482

COMPLETED NA 227 participants

Exercise Cardiac Magnetic Resonance Imaging Accuracy for Cardiovascular Stress Testing

Ohio State University

NCT01592565

COMPLETED Phase 4 212 participants

The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)

Johns Hopkins University

NCT02683707

COMPLETED 201 participants

Non-Invasive EndoPAT Increases Diagnostic Yield of CAD by Coronary Angiography

Mayo Clinic

NCT01581671

COMPLETED NA 200 participants

Analysis of Surface EKG Signals to Identify Myocardial Dysfunction in Patients at Risk for Coronary Artery Disease

Icahn School of Medicine at Mount Sinai

NCT02560168

COMPLETED 198 participants

Determinants of Cardiac Risk Factor Modification in Latinos With Coronary Artery Disease

Weill Medical College of Cornell University

NCT00248859

COMPLETED 191 participants

WARRIOR Ancillary Study for CCTA Analysis

Cedars-Sinai Medical Center

NCT05035056

← Previous Page 3 of 5 Next →

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 9
Phase 3 17
Phase 4 25

Named interventions

Most-linked intervention names on Coronary Artery Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
7 trials
Ticagrelor Drug
4 trials
Placebo Other
4 trials
Colchicine Drug
3 trials
Clopidogrel Drug
3 trials
PROMUS Element Coronary Stent System Device
2 trials
Corus CAD (ASGES) Diagnostic test
2 trials
Percutaneous coronary intervention Device
2 trials

US sites by state

Facility locations filed on Coronary Artery Disease trials. A trial with sites in several states counts in each.

California 75 trials
New York 61 trials
Florida 58 trials
Georgia 40 trials
Massachusetts 36 trials
Minnesota 31 trials
Illinois 30 trials
Ohio 29 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Coronary Artery Disease page

220 registered trials, 57 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 57 Coronary Artery Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • University of Florida sponsors the most Coronary Artery Disease trials on record, review their full trial history before evaluating a specific study. See University of Florida's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Coronary Artery Disease condition card totals 220 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.